Find Health Canada Patents Information with Patent Number, Filing Date and Patent Expiration Date of MolPort-000-883-860 on PharmaCompass.com

PharmaCompass

Synopsis

Synopsis

ACTIVE PHARMA INGREDIENTS

0

CEP/COS

CEP/COS Certifications

0

JDMF

JDMFs Filed

0

KDMF

KDMF

0

VMF

NDC API

API REF. PRICE (USD/KG)

MARKET PLACE

0

API

0

FDF

FINISHED DOSAGE FORMULATIONS

0

Canada

Canada

0

Australia

Australia

0

South Africa

South Africa

0 DRUGS IN DEVELOPMENT

FDF DossiersDRUG PRODUCT COMPOSITIONS

REF. STANDARDS OR IMPURITIES

0

EDQM

0

JP

PATENTS & EXCLUSIVITIES

0

US Patents

0

US Exclusivities

DIGITAL CONTENT

0

Data Compilation #PharmaFlow

0

Stock Recap #PipelineProspector

0

Weekly News Recap #Phispers

GLOBAL SALES INFORMATION

Annual Reports

NA

156 RELATED EXCIPIENT COMPANIES

256EXCIPIENTS BY APPLICATIONS

Chemistry

Click the arrow to open the dropdown
read-moreClick the button for full data set
Also known as: 151319-34-5, Sonata, Cl-284846, Skp-1041, N-[3-(3-cyanopyrazolo[1,5-a]pyrimidin-7-yl)phenyl]-n-ethylacetamide, Zal-846
Molecular Formula
C17H15N5O
Molecular Weight
305.33  g/mol
InChI Key
HUNXMJYCHXQEGX-UHFFFAOYSA-N
FDA UNII
S62U433RMH

Zaleplon
Zaleplon is a nonbenzodiazepine from the pyrazolopyrimidine class with hypnotic, sedative, anxiolytic, and muscle relaxant properties. Zaleplon interacts with the gamma-aminobutyric acid (GABA) -A receptor, thereby affecting the chloride channel ionophore complex and potentiating the inhibitory effects of GABA. In addition, zaleplon binds selectively to the brain omega-1 receptor situated on the alpha subunit of the GABA-A/chloride ion channel receptor complex and potentiates t-butyl-bicyclophosphorothionate (TBPS) binding.
Zaleplon is a gamma-Aminobutyric Acid A Receptor Agonist. The mechanism of action of zaleplon is as a GABA A Agonist. The physiologic effect of zaleplon is by means of Central Nervous System Depression.
1 2D Structure

Zaleplon

2 Identification
2.1 Computed Descriptors
2.1.1 IUPAC Name
N-[3-(3-cyanopyrazolo[1,5-a]pyrimidin-7-yl)phenyl]-N-ethylacetamide
2.1.2 InChI
InChI=1S/C17H15N5O/c1-3-21(12(2)23)15-6-4-5-13(9-15)16-7-8-19-17-14(10-18)11-20-22(16)17/h4-9,11H,3H2,1-2H3
2.1.3 InChI Key
HUNXMJYCHXQEGX-UHFFFAOYSA-N
2.1.4 Canonical SMILES
CCN(C1=CC=CC(=C1)C2=CC=NC3=C(C=NN23)C#N)C(=O)C
2.2 Other Identifiers
2.2.1 UNII
S62U433RMH
2.3 Synonyms
2.3.1 MeSH Synonyms

1. 3'-(3-cyanopyrazolo(1,5-alpha)pyrimidin-7-yl)-n-ethylacetanilide

2. Cl 284,846

3. Cl 284846

4. Cl-284846

5. Cl284,846

6. L 846

7. L-846

8. N-(3-(3-cyanopyrazolo(1,5-a)pyrimidin-7-yl)phenyl)-n-ethylacetamide

9. Skp-1041

10. Sonata

11. Starnoc

12. Zelepion

2.3.2 Depositor-Supplied Synonyms

1. 151319-34-5

2. Sonata

3. Cl-284846

4. Skp-1041

5. N-[3-(3-cyanopyrazolo[1,5-a]pyrimidin-7-yl)phenyl]-n-ethylacetamide

6. Zal-846

7. Cl 284,846

8. Ljc 10846

9. L846

10. Cl 284846

11. Ljc-10846

12. L-846

13. Dea No. 2781

14. Zaleplon Civ

15. 3'-(3-cyanopyrazolo(1,5-a)pyrimidin-7-yl)-n-ethylacetanilide

16. N-(3-(3-cyanopyrazolo(1,5-a)pyrimidin-7-yl)phenyl)-n-ethylacetamide

17. S62u433rmh

18. Chebi:10102

19. N-(3-(3-cyanopyrazolo[1,5-a]pyrimidin-7-yl)phenyl)-n-ethylacetamide

20. Ncgc00160525-01

21. Dsstox_cid_3748

22. Dsstox_rid_77183

23. Dsstox_gsid_23748

24. Zal 846

25. N-(3-{3-cyanopyrazolo[1,5-a]pyrimidin-7-yl}phenyl)-n-ethylacetamide

26. Staccato-zaleplon

27. Smr000238180

28. Sonata (tn)

29. Cas-151319-34-5

30. Unii-s62u433rmh

31. Zaleplon Ap

32. Zaleplon [usan:usp:inn:ban]

33. 3'-(3-cyanopyrazolo(1,5-alpha)pyrimidin-7-yl)-n-ethylacetanilide

34. Az-007

35. Zaleplon [usan]

36. Zaleplon [inn]

37. Zaleplon [jan]

38. Zaleplon [mi]

39. Zaleplon [vandf]

40. Zaleplon [mart.]

41. Zaleplon [who-dd]

42. Acetamide, N-(3-(3-cyanopyrazolo(1,5-a)pyrimidin-7-yl)phenyl)-n-ethyl-

43. Zaleplon (jan/usp/inn)

44. Chembl1521

45. Zaleplon [ema Epar]

46. Schembl29118

47. Mls000759451

48. Mls001424238

49. Bidd:gt0046

50. Zaleplon [orange Book]

51. Zaleplon Civ [usp-rs]

52. Gtpl4345

53. Zinc6300

54. Dtxsid5023748

55. Zaleplon [usp Monograph]

56. Bdbm86521

57. Zaleplon 1.0 Mg/ml In Methanol

58. Hms2052j11

59. Hms3394j11

60. Hms3713h08

61. Act04427

62. Bcp21340

63. Cas_5719

64. Nsc_5719

65. Tox21_111872

66. N-[3-(3-cyanopyrazolo[1,5-a]pyrimidin-7-yl)phenyl]-n-ethyl-acetamide

67. Zaleplon, >=98% (hplc), Solid

68. Acetamide, N-(3-(3-cyanopyrazolo(1,5-alpha)pyrimidin-7-yl)phenyl)-n-ethyl-

69. Akos000280863

70. Tox21_111872_1

71. Ac-2082

72. Ccg-101187

73. Db00962

74. Nc00437

75. Ss-4571

76. Ncgc00160525-02

77. Hy-14265

78. Db-015068

79. A12993

80. C07484

81. D00530

82. Ab00640003_03

83. 319z345

84. A809159

85. Q145052

86. Sr-01000759426

87. Sr-01000759426-3

88. Zaleplon, United States Pharmacopeia (usp) Reference Standard

89. N-[3-(cyanopyrazolo[1,5-a]pyrimidin-7-yl)phenyl]-n-ethylacetamide

90. 3'-(3-cyanopyrazolo(1,5-.alpha.)pyrimidin-7-yl)-n-ethylacetanilide

91. N-[3-(3-cyanopyrazolo-[1,5-a]-pyrimidin-7-yl)-phenyl]-n-ethyl Acetamide

92. Acetamide, N-(3-(3-cyanopyrazolo(1,5-.alpha.)pyrimidin-7-yl)phenyl)-n-ethyl-

93. Zaleplon Solution, 1.0 Mg/ml In Methanol, Ampule Of 1 Ml, Certified Reference Material

94. 1007130-22-4

2.4 Create Date
2005-03-25
3 Chemical and Physical Properties
Molecular Weight 305.33 g/mol
Molecular Formula C17H15N5O
XLogP31
Hydrogen Bond Donor Count0
Hydrogen Bond Acceptor Count4
Rotatable Bond Count3
Exact Mass305.12766012 g/mol
Monoisotopic Mass305.12766012 g/mol
Topological Polar Surface Area74.3 Ų
Heavy Atom Count23
Formal Charge0
Complexity487
Isotope Atom Count0
Defined Atom Stereocenter Count0
Undefined Atom Stereocenter Count0
Defined Bond Stereocenter Count0
Undefined Bond Stereocenter Count0
Covalently Bonded Unit Count1
4 Drug and Medication Information
4.1 Drug Information
1 of 4  
Drug NameSonata
PubMed HealthZaleplon (By mouth)
Drug ClassesNonbarbiturate Hypnotic
Drug LabelZaleplon is a nonbenzodiazepine hypnotic from the pyrazolopyrimidine class. The chemical name of zaleplon is N-[3-(3-cyanopyrazolo[1,5-a]pyrimidin-7-yl)phenyl]-N-ethylacetamide. Its empirical formula is C17H15N5O, and its molecular weight is 305.34....
Active IngredientZaleplon
Dosage FormCapsule
RouteOral
Strength5mg; 10mg
Market StatusPrescription
CompanyPfizer

2 of 4  
Drug NameZaleplon
PubMed HealthZaleplon (By mouth)
Drug ClassesNonbarbiturate Hypnotic
Drug LabelZaleplon is a nonbenzodiazepine hypnotic from the pyrazolopyrimidine class. The chemical name of zaleplon is N-[3-(3-cyanopyrazolo[1,5-a]pyrimidin-7-yl)phenyl]-N-ethylacetamide. Its empirical formula is C17H15N5O, and its molecular weight is 305.34....
Active IngredientZaleplon
Dosage FormCapsule
RouteOral
Strength5mg; 10mg
Market StatusPrescription
CompanyUpsher Smith; Unichem; Aurobindo Pharma; Cipla; Hikma Pharms; Roxane; Teva Pharms; Orchid Hlthcare; Mylan

3 of 4  
Drug NameSonata
PubMed HealthZaleplon (By mouth)
Drug ClassesNonbarbiturate Hypnotic
Drug LabelZaleplon is a nonbenzodiazepine hypnotic from the pyrazolopyrimidine class. The chemical name of zaleplon is N-[3-(3-cyanopyrazolo[1,5-a]pyrimidin-7-yl)phenyl]-N-ethylacetamide. Its empirical formula is C17H15N5O, and its molecular weight is 305.34....
Active IngredientZaleplon
Dosage FormCapsule
RouteOral
Strength5mg; 10mg
Market StatusPrescription
CompanyPfizer

4 of 4  
Drug NameZaleplon
PubMed HealthZaleplon (By mouth)
Drug ClassesNonbarbiturate Hypnotic
Drug LabelZaleplon is a nonbenzodiazepine hypnotic from the pyrazolopyrimidine class. The chemical name of zaleplon is N-[3-(3-cyanopyrazolo[1,5-a]pyrimidin-7-yl)phenyl]-N-ethylacetamide. Its empirical formula is C17H15N5O, and its molecular weight is 305.34....
Active IngredientZaleplon
Dosage FormCapsule
RouteOral
Strength5mg; 10mg
Market StatusPrescription
CompanyUpsher Smith; Unichem; Aurobindo Pharma; Cipla; Hikma Pharms; Roxane; Teva Pharms; Orchid Hlthcare; Mylan

4.2 Drug Indication

For the treatment of short-term treatment of insomnia in adults.


FDA Label


Sonata is indicated for the treatment of patients with insomnia who have difficulty falling asleep. It is indicated only when the disorder is severe, disabling or subjecting the individual to extreme distress.


5 Pharmacology and Biochemistry
5.1 Pharmacology

Zaleplon is a nonbenzodiazepine hypnotic from the pyrazolopyrimidine class and is indicated for the short-term treatment of insomnia. While Zaleplon is a hypnotic agent with a chemical structure unrelated to benzodiazepines, barbiturates, or other drugs with known hypnotic properties, it interacts with the gamma-aminobutyric acid-benzodiazepine (GABABZ) receptor complex. Subunit modulation of the GABABZ receptor chloride channel macromolecular complex is hypothesized to be responsible for some of the pharmacological properties of benzodiazepines, which include sedative, anxiolytic, muscle relaxant, and anticonvulsive effects in animal models. Zaleplon also binds selectively to the CNS GABAA-receptor chloride ionophore complex at benzodiazepine(BZ) omega-1 (BZ1, 1) receptors.


5.2 MeSH Pharmacological Classification

Anticonvulsants

Drugs used to prevent SEIZURES or reduce their severity. (See all compounds classified as Anticonvulsants.)


Hypnotics and Sedatives

Drugs used to induce drowsiness or sleep or to reduce psychological excitement or anxiety. (See all compounds classified as Hypnotics and Sedatives.)


GABA Modulators

Substances that do not act as agonists or antagonists but do affect the GAMMA-AMINOBUTYRIC ACID receptor-ionophore complex. GABA-A receptors (RECEPTORS, GABA-A) appear to have at least three allosteric sites at which modulators act: a site at which BENZODIAZEPINES act by increasing the opening frequency of GAMMA-AMINOBUTYRIC ACID-activated chloride channels; a site at which BARBITURATES act to prolong the duration of channel opening; and a site at which some steroids may act. GENERAL ANESTHETICS probably act at least partly by potentiating GABAergic responses, but they are not included here. (See all compounds classified as GABA Modulators.)


5.3 FDA Pharmacological Classification
5.3.1 Active Moiety
ZALEPLON
5.3.2 FDA UNII
S62U433RMH
5.3.3 Pharmacological Classes
GABA A Agonists [MoA]; gamma-Aminobutyric Acid A Receptor Agonist [EPC]; Central Nervous System Depression [PE]
5.4 ATC Code

N05CF03


N - Nervous system

N05 - Psycholeptics

N05C - Hypnotics and sedatives

N05CF - Benzodiazepine related drugs

N05CF03 - Zaleplon


5.5 Absorption, Distribution and Excretion

Absorption

Absorption Zaleplon is rapidly and almost completely absorbed following oral administration.


Route of Elimination

Zaleplon is metabolized primarily by the liver and undergoes significant presystemic metabolism. After oral administration, zaleplon is extensively metabolized, with less than 1% of the dose excreted unchanged in urine. Renal excretion of unchanged zaleplon accounts for less than 1% of the administered dose.


Volume of Distribution

1.4 L/kg


Clearance

1 L/h/kg


5.6 Metabolism/Metabolites

Zaleplon is primarily metabolized by aldehyde oxidase.


Zaleplon has known human metabolites that include Dementhylazed-zaleplon.

S73 | METXBIODB | Metabolite Reaction Database from BioTransformer | DOI:10.5281/zenodo.4056560


5.7 Biological Half-Life

Approximately 1 hour


5.8 Mechanism of Action

Zaleplon exerts its action through subunit modulation of the GABABZ receptor chloride channel macromolecular complex. Zaleplon also binds selectively to the brain omega-1 receptor located on the alpha subunit of the GABA-A/chloride ion channel receptor complex and potentiates t-butyl-bicyclophosphorothionate (TBPS) binding.


API SUPPLIERS

read-more
read-more

01

Teva API

Israel

USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

Boulder Peptide 2024
Not Confirmed
arrow

Teva API

Israel

USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

arrow
Boulder Peptide 2024
Not Confirmed
USDMF arrow-down Click Us! arrow-down
CEP/COS JDMF EU-WC NDC KDMF VMF Others AUDIT
blank

02

Orchid Pharma

India

USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

Boulder Peptide 2024
Not Confirmed
arrow

Orchid Pharma

India

USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

arrow
Boulder Peptide 2024
Not Confirmed
USDMF arrow-down CEP/COS JDMF EU-WC NDC KDMF VMF Others AUDIT
blank

03

Aurobindo Pharma Limited

India

USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

Boulder Peptide 2024
Not Confirmed
arrow

Aurobindo Pharma Limited

India

USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

arrow
Boulder Peptide 2024
Not Confirmed
USDMF arrow-down CEP/COS JDMF EU-WCarrow-down NDC arrow-down KDMF VMF Others AUDIT
blank

04

Centaur Pharmaceuticals

India

USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

Boulder Peptide 2024
Not Confirmed
arrow

Centaur Pharmaceuticals

India

USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

arrow
Boulder Peptide 2024
Not Confirmed
USDMF arrow-down CEP/COS JDMF EU-WCarrow-down NDC arrow-down KDMF VMF Others AUDIT
blank

05

Amino Chemicals

Malta

USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

Boulder Peptide 2024
Not Confirmed
arrow

Amino Chemicals

Malta

USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

arrow
Boulder Peptide 2024
Not Confirmed
USDMF Inactive-api CEP/COS JDMF EU-WC NDC KDMF VMF Others AUDIT
blank

06

Gador SA

Argentina

USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

Boulder Peptide 2024
Not Confirmed
arrow

Gador SA

Argentina

USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

arrow
Boulder Peptide 2024
Not Confirmed
USDMF Inactive-api CEP/COS JDMF EU-WC NDC KDMF VMF Others AUDIT
blank

07

Apotex Pharmachem

Canada

USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

Boulder Peptide 2024
Not Confirmed
arrow

Apotex Pharmachem

Canada

USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

arrow
Boulder Peptide 2024
Not Confirmed
USDMF Inactive-api CEP/COS JDMF EU-WC NDC KDMF VMF Others AUDIT
blank

08

Zydus Lifesciences

India

USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

Boulder Peptide 2024
Not Confirmed
arrow

Zydus Lifesciences

India

USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

arrow
Boulder Peptide 2024
Not Confirmed
USDMF Inactive-api CEP/COS JDMF EU-WC NDC KDMF VMF Others AUDIT
blank

09

Cipla

India

USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

Boulder Peptide 2024
Not Confirmed
arrow

Cipla

India

USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

arrow
Boulder Peptide 2024
Not Confirmed
USDMF Inactive-api CEP/COS JDMF EU-WC NDC KDMF VMF Others AUDIT
blank

10

Chromo Laboratories

India

USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

Boulder Peptide 2024
Not Confirmed
arrow

Chromo Laboratories

India

USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

arrow
Boulder Peptide 2024
Not Confirmed
USDMF CEP/COS JDMF EU-WCInactive-api NDC arrow-down KDMF VMF Others AUDIT
blank
click full view
Full Screen ViewFULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

USDMF

read-more
read-more

01

Amino Chemicals Ltd

Malta

USDMF

arrow
Boulder Peptide 2024
Not Confirmed

01

Boulder Peptide 2024
Not Confirmed

GDUFA

DMF Review : N/A

Rev. Date :

Pay. Date :

DMF Number : 16785

Submission : 2003-08-20

Status : Inactive

Type : II

blank

02

Apotex Pharmachem Inc

Canada

USDMF

arrow
Boulder Peptide 2024
Not Confirmed

02

Boulder Peptide 2024
Not Confirmed

GDUFA

DMF Review : N/A

Rev. Date :

Pay. Date :

DMF Number : 22572

Submission : 2009-02-25

Status : Inactive

Type : II

blank

03

Boulder Peptide 2024
Not Confirmed

04

Cipla Ltd

India

USDMF

arrow
Boulder Peptide 2024
Not Confirmed

04

Cipla Ltd

India
arrow
Boulder Peptide 2024
Not Confirmed

GDUFA

DMF Review : N/A

Rev. Date :

Pay. Date :

DMF Number : 18022

Submission : 2005-01-26

Status : Inactive

Type : II

blank

05

Gador Sa

Argentina

USDMF

arrow
Boulder Peptide 2024
Not Confirmed

05

Gador Sa

Argentina
arrow
Boulder Peptide 2024
Not Confirmed

GDUFA

DMF Review : N/A

Rev. Date :

Pay. Date :

DMF Number : 19015

Submission : 2005-12-13

Status : Inactive

Type : II

blank

06

Boulder Peptide 2024
Not Confirmed

07

Boulder Peptide 2024
Not Confirmed

08

Cadila Healthcare Ltd

India

USDMF

arrow
Boulder Peptide 2024
Not Confirmed

08

Boulder Peptide 2024
Not Confirmed

GDUFA

DMF Review : N/A

Rev. Date :

Pay. Date :

DMF Number : 21482

Submission : 2008-04-01

Status : Inactive

Type : II

blank
Full Screen ViewFULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

API Reference Price

read-more
read-more
[{"dataSource":"API Export","activeIngredients":"","year":"2021","qtr":"Q3","strtotime":1630261800,"product":"ZALEPLON USP [ACTIVE PHARMACEUTICAL INGR","address":"CENTAUR HOUSE, SHANTI NAGAR,VAKOLA, SANTACRUZ (E),","city":"MUMBAI ,MAHARASHTRA","supplier":"CENTAUR PHARMACEUTICALS","supplierCountry":"INDIA","foreign_port":"SEOUL - INCHEON INT\\'","customer":"M\/S.","customerCountry":"KOREA, REPUBLIC OF","quantity":"2.00","actualQuantity":"2","unit":"KGS","unitRateFc":"1500","totalValueFC":"2966.3","currency":"USD","unitRateINR":110000,"date":"30-Aug-2021","totalValueINR":"220000","totalValueInUsd":"2966.3","indian_port":"BOMBAY AIR","hs_no":"29420090","bill_no":"4216635","productDescription":"API","marketType":"REGULATED MARKET","country":"KOREA,REPUBLIC OF","selfForZScoreResived":"Pharma Grade","supplierPort":"BOMBAY AIR","supplierAddress":"CENTAUR HOUSE, SHANTI NAGAR,VAKOLA, SANTACRUZ (E),, MUMBAI ,MAHARASHTRA","customerAddress":""},{"dataSource":"API Export","activeIngredients":"","year":"2022","qtr":"Q2","strtotime":1650565800,"product":"ZALEPLON USP [ACTIVE PHARMACEUTICAL INGR","address":"CENTAUR HOUSE, SHANTI NAGAR,,VAKOL A, SANTACRUZ - EAST","city":"MUMBAI,MAHARASHTRA","supplier":"CENTAUR PHARMACEUTICALS","supplierCountry":"INDIA","foreign_port":"SEOUL - INCHEON INT\\'","customer":"M\/S.","customerCountry":"KOREA, REPUBLIC OF","quantity":"2.10","actualQuantity":"2.1","unit":"KGS","unitRateFc":"1500","totalValueFC":"3127.9","currency":"USD","unitRateINR":112380.95238095238,"date":"22-Apr-2022","totalValueINR":"236000","totalValueInUsd":"3127.9","indian_port":"BOMBAY AIR","hs_no":"29420090","bill_no":"9867887","productDescription":"API","marketType":"REGULATED MARKET","country":"KOREA,REPUBLIC OF","selfForZScoreResived":"Pharma Grade","supplierPort":"BOMBAY AIR","supplierAddress":"CENTAUR HOUSE, SHANTI NAGAR,,VAKOL A, SANTACRUZ - EAST, MUMBAI,MAHARASHTRA","customerAddress":""},{"dataSource":"API Export","activeIngredients":"","year":"2022","qtr":"Q3","strtotime":1658773800,"product":"ZALEPLON USP","address":"PLOT NO:65, SECTOR-I","city":"PITHAMPUR DIST:DHAR (MP)","supplier":"VINDAS CHEMICAL INDUSTRIES PRIVATE LIMITED","supplierCountry":"INDIA","foreign_port":"MUKALLA","customer":"TO THE ORDER OF","customerCountry":"YEMEN","quantity":"1.00","actualQuantity":"1","unit":"KGS","unitRateFc":"939.3","totalValueFC":"943.2","currency":"EUR","unitRateINR":75000,"date":"26-Jul-2022","totalValueINR":"75000","totalValueInUsd":"943.2","indian_port":"JNPT","hs_no":"29242990","bill_no":"3067605","productDescription":"API","marketType":"LESS REGULATED MARKET","country":"YEMEN, DEMOCRATIC","selfForZScoreResived":"Pharma Grade","supplierPort":"JNPT","supplierAddress":"PLOT NO:65, SECTOR-I, PITHAMPUR DIST:DHAR (MP)","customerAddress":""},{"dataSource":"API Export","activeIngredients":"","year":"2022","qtr":"Q3","strtotime":1660156200,"product":"ZALEPLON USP 2022","address":"SHOP NO. D-4, NEELKANTH BUSINESS,P ARK CO-OP PREMISES SOCIETY LTD.","city":"NATHANI ROAD VIDHYA VIHAR WEST,MAHA","supplier":"PRECISE CHEMIPHARMA P LTD","supplierCountry":"INDIA","foreign_port":"CAIRO","customer":"OCTOBER PHARMA S.A.E.","customerCountry":"EGYPT","quantity":"10.00","actualQuantity":"10","unit":"KGS","unitRateFc":"735","totalValueFC":"7138.6","currency":"USD","unitRateINR":56800,"date":"11-Aug-2022","totalValueINR":"568000","totalValueInUsd":"7138.6","indian_port":"BOMBAY AIR","hs_no":"29242990","bill_no":"3436381","productDescription":"API","marketType":"LESS REGULATED MARKET","country":"EGYPT","selfForZScoreResived":"Pharma Grade","supplierPort":"BOMBAY AIR","supplierAddress":"SHOP NO. D-4, NEELKANTH BUSINESS,P ARK CO-OP PREMISES SOCIETY LTD., NATHANI ROAD VIDHYA VIHAR WEST,MAHA","customerAddress":""},{"dataSource":"API Export","activeIngredients":"","year":"2023","qtr":"Q1","strtotime":1675708200,"product":"ZALEPLON USP [ACTIVE PHARMACEUTICAL INGR","address":"CENTAUR HOUSE, SHANTI NAGAR,,VAKOL A, SANTACRUZ - EAST","city":"MUMBAI,MAHARASHTRA","supplier":"CENTAUR PHARMACEUTICALS","supplierCountry":"INDIA","foreign_port":"SEOUL - INCHEON INT\\'","customer":"TO THE ORDER OF","customerCountry":"KOREA, REPUBLIC OF","quantity":"11.95","actualQuantity":"11.95","unit":"KGS","unitRateFc":"1395","totalValueFC":"16248.9","currency":"USD","unitRateINR":112301.25523012553,"date":"07-Feb-2023","totalValueINR":"1342000","totalValueInUsd":"16248.9","indian_port":"BOMBAY AIR","hs_no":"29420090","bill_no":"7598432","productDescription":"API","marketType":"REGULATED MARKET","country":"KOREA,REPUBLIC OF","selfForZScoreResived":"Pharma Grade","supplierPort":"BOMBAY AIR","supplierAddress":"CENTAUR HOUSE, SHANTI NAGAR,,VAKOL A, SANTACRUZ - EAST, MUMBAI,MAHARASHTRA","customerAddress":""},{"dataSource":"API Export","activeIngredients":"","year":"2023","qtr":"Q2","strtotime":1687113000,"product":"ZALEPLON","address":"`Jay House\\' House No.- 4. 2nd Floor Magnet Corporate Park, B\/h, Intas H","city":"AHMEDABAD","supplier":"V 2 IMPEX","supplierCountry":"INDIA","foreign_port":"SALALAH","customer":"ALWATANYAH MODERN FOR ","customerCountry":"OMAN","quantity":"7.00","actualQuantity":"7","unit":"KGS","unitRateFc":"955.8","totalValueFC":"6618.3","currency":"USD","unitRateINR":77714.324999999997,"date":"19-Jun-2023","totalValueINR":"544000.275","totalValueInUsd":"6618.3","indian_port":"AHMEDABAD ICD","hs_no":"29242990","bill_no":"0","productDescription":"API","marketType":"LESS REGULATED MARKET","country":"OMAN","selfForZScoreResived":"Pharma Grade","supplierPort":"AHMEDABAD ICD","supplierAddress":"`Jay House\\' House No.- 4. 2nd Floor Magnet Corporate Park, B\/h, Intas H, AHMEDABAD","customerAddress":""},{"dataSource":"API Export","activeIngredients":"","year":"2023","qtr":"Q4","strtotime":1698258600,"product":"ZALEPLON USP","address":"JAY HOUSE, B-1, KUMUD APPARTMENT,","city":"AHMEDABAD","supplier":"V 2 IMPEX","supplierCountry":"INDIA","foreign_port":"SALALAH","customer":"MAF PHARMA FOR PHARMACEUTICAL INDUS","customerCountry":"OMAN","quantity":"10.00","actualQuantity":"10","unit":"KGS","unitRateFc":"869.6","totalValueFC":"8611.9","currency":"USD","unitRateINR":71700,"date":"26-Oct-2023","totalValueINR":"717000","totalValueInUsd":"8611.9","indian_port":"Ahmedabad ICD","hs_no":"29242990","bill_no":"4908737","productDescription":"API","marketType":"LESS REGULATED MARKET","country":"OMAN","selfForZScoreResived":"Pharma Grade","supplierPort":"Ahmedabad ICD","supplierAddress":"JAY HOUSE, B-1, KUMUD APPARTMENT,, AHMEDABAD","customerAddress":""}]
30-Aug-2021
26-Oct-2023
KGS
overview
Loading...

Average Price (USD/KGS)

Number of Transactions

Total Quantity (KGS)

Total Value (USD)

Quantity (KGS) & Unit rate (USD/KGS) over time

API Imports and Exports

Importing Country Total Quantity
(KGS)
Average Price
(USD/KGS)
Number of Transactions

Upgrade, download data, analyse, strategize, subscribe with us contact

INTERMEDIATES SUPPLIERS

read-more
read-more

01

Boulder Peptide 2024
Not Confirmed
arrow
Boulder Peptide 2024
Not Confirmed
arrow

CAS Number : 16617-46-2

End Use API : Zaleplon

About The Company : Enal Drugs Private Limited,an ISO 9001 : 2000 certified company, specializes in developing and producing anti ulcerative drugs, their intermediates, other activ...

blank

02

Boulder Peptide 2024
Not Confirmed
arrow
Boulder Peptide 2024
Not Confirmed
arrow

CAS Number : 16617-46-2

End Use API : Zaleplon

About The Company : Enal Drugs Private Limited,an ISO 9001 : 2000 certified company, specializes in developing and producing anti ulcerative drugs, their intermediates, other activ...

blank

03

Boulder Peptide 2024
Not Confirmed
arrow
Boulder Peptide 2024
Not Confirmed
arrow

CAS Number : 75-03-6

End Use API : Zaleplon

About The Company : At Infinium Pharmachem Pvt. Ltd., we are well focused to Iodine chemistry & this is the only core area of ours. We are working as CRAMS, but our domain is very ...

blank
Full Screen ViewFULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

DRUG PRODUCT COMPOSITIONS

Do you need Business Intel? Ask us

DOSAGE - CAPSULE;ORAL - 10MG

USFDA APPLICATION NUMBER - 20859

read-more

DOSAGE - CAPSULE;ORAL - 5MG

USFDA APPLICATION NUMBER - 20859

read-more

Related Excipient Companies

Upload your portfolio for free, ask us

Excipients by Applications

Click here to find the perfect excipient manufacturers by their capabilities

Fillers, Diluents & Binders

read-more
read-more

Direct Compression

read-more
read-more

Thickeners and Stabilizers

read-more
read-more

Granulation

read-more
read-more

Lubricants & Glidants

read-more
read-more

Coating Systems & Additives

read-more
read-more

Co-Processed Excipients

read-more
read-more

Topical

read-more
read-more

Controlled & Modified Release

read-more
read-more

Disintegrants & Superdisintegrants

read-more
read-more

Film Formers & Plasticizers

read-more
read-more

Empty Capsules

read-more
read-more

Taste Masking

read-more
read-more

Solubilizers

read-more
read-more

Chewable & Orodispersible Aids

read-more
read-more

Parenteral

read-more
read-more

Emulsifying Agents

read-more
read-more

Coloring Agents

read-more
read-more

API Stability Enhancers

read-more
read-more

Surfactant & Foaming Agents

read-more
read-more

Rheology Modifiers

read-more
read-more

Digital Content read-more

Create Content with PharmaCompass, ask us

NEWS #PharmaBuzz

read-more
read-more

Global Sales Information

Do you need Business Intel? Ask us

Patents & EXCLUSIVITIES

Check the patents & exclusivity for this product

REF. STANDARDS & IMPURITIES

Upload your portfolio for free, ask us

ABOUT THIS PAGE

Ask Us for Pharmaceutical Supplier and Partner
Ask Us, Find A Supplier / Partner
No Commissions, No Strings Attached, Get Connected for FREE

What are you looking for?

How can we help you?

The request can't be empty

Please read our Privacy Policy carefully

You must agree to the privacy policy

The name can't be empty
The company can't be empty.
The email can't be empty Please enter a valid email.
The mobile can't be empty